Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The Lancet Oncology

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(18)30072-XPMID 29429912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Healthcare resource use and costs associated with renal impairment in US patients with bone metastases from solid tumors

  2017cited by this paper
• Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

  2016cited by this paper
• Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

  2015cited by this paper
• Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

  2015cited by this paper
• Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

  2015cited by this paper
• Role of osteocytes in multiple myeloma bone disease

  2014cited by this paper
• Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement

  2013cited by this paper
• Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

  2013cited by this paper
• Epidemiology of multiple myeloma.

  2011cited by this paper
• Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

  2011cited by this paper
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  2011cited by this paper
• Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

  2011cited by this paper
• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

  2010cited by this paper
• Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.

  2008cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

  2006cited by this paper
• Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

  2006cited by this paper
• Zoledronic acid down‐regulates adhesion molecules of bone marrow stromal cells in multiple myeloma

  2005cited by this paper
• Cancer and the Microenvironment

  2004cited by this paper
• Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

  2004cited by this paper
• Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation

  2004cited by this paper
• Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

  2003cited by this paper
• Assessing treatment efficacy in noninferiority trials.

  2003cited by this paper
• Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis

  2001cited by this paper
• Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests

  2000cited by this paper
• Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

  1998cited by this paper
• Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity

  1997cited by this paper
• Regression analysis of multivariate incomplete failure time data by modeling marginal distributions

  1989cited by this paper
• Cox's regression model for counting processes: a large sample study : (preprint)

  1982cited by this paper

• Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis

  2026cites this paper
• Rho-related GTP-binding protein RhoE (RND3) regulates multiple myeloma bone disease

  2026cites this paper
• Identifying the clinical indicator for surgical intervention in medication-related osteonecrosis of the jaw.

  2026cites this paper
• Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice

  2026cites this paper
• Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.

  2026cites this paper
• Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.

  2026cites this paper
• Multiple Myeloma Management in a Large Low- and Middle-Income Country: Lessons From India in Balancing Cost and Clinical Efficacy in Resource-Limited Settings.

  2026cites this paper
• Which monoclonal antibodies cause osteonecrosis of the jaws? An overview of the current literature excluding denosumab.

  2026cites this paper
• Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study.

  2026cites this paper
• Drug-related proteinuria: a vigilance analysis based on the FAERS database.

  2026cites this paper
• Impact of treatment delay of multiple myeloma bone disease on later myeloma-related skeletal events and outcome

  2025cites this paper
• Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events

  2025cites this paper
• Treatment of myeloma bone disease: When, how often, and for how long?

  2025influential citation
• Medication-related osteonecrosis of the jaw: an evidence-based 2025 position statement from a Korean multidisciplinary task force

  2025influential citation
• A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy

  2025influential citation
• LY6E as a new prognostic biomarker of multiple myeloma-related bone disease

  2025cites this paper
• Systemic bone loss measured by routine CT is associated with increased pain, postural decompensation, and survival in multiple myeloma

  2025cites this paper
• Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics

  2025cites this paper
• Prognostic Significance of the Density and Spatial Distribution of Tumor‐Associated Macrophages in Giant Cell Tumor of Bone and Their Association With Denosumab Treatment Responsiveness

  2025cites this paper
• Establishment and comprehensive characterization of a subline with highly bone-metastatic propensity derived from the lung adenocarcinoma A549 cell line

  2025cites this paper
• Myeloma bone disease: A constant problem in the changing landscape of myeloma management

  2025cites this paper
• Role of Denosumab in Patients with Intermediate Spinal Instability Neoplastic Score (SINS)

  2025cites this paper
• Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial

  2025cites this paper
• The Microbiological Background of Medication-Related Osteonecrosis of the Jaw (MRONJ): Clinical Evidence Based on Traditional Culture and Molecular Biological Detection Methods

  2025cites this paper
• Successful rapid desensitization to zoledronic acid in a multiple myeloma patient

  2025cites this paper
• Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives

  2025cites this paper
• Circular RNA hsa_Circ_0007552 inhibits lung adenocarcinoma proliferation, migration and invasion via the miR-7974/BAP1 axis

  2025cites this paper
• Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2025influential citation
• RANKL promotes MT2 degradation and ROS production in osteoclast precursors through Beclin1-dependent autophagy.

  2025cites this paper
• Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies.

  2025cites this paper
• Advancements in Multiple Myeloma Therapies: A Comprehensive Review by Disease Stage

  2025cites this paper
• Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.

  2025cites this paper
• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

  2025influential citation
• Myeloma interaction with bone marrow stromal cells suppresses ciliogenesis and osteogenic potential in myeloma bone disease.

  2025cites this paper
• Fractures incidence and its association on mortality in multiple myeloma patients: a nationwide cohort study (CAREMM-2105 study)

  2025cites this paper
• Adipocyte–Tumor Interactions in the Bone Marrow Niche: Implications for Metastasis and Therapy

  2025cites this paper
• Trends in mortality of renal failure in adult multiple myeloma patients: a CDC data analysis (1999–2020)

  2025cites this paper
• Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma.

  2025cites this paper
• Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

  2025influential citation
• Cost-Effectiveness of Denosumab for Treating Bone Metastases from Solid Tumors: A Systematic Review (2017-2023).

  2025cites this paper
• Efficacy of Bone-Modifying Agents in Preventing Vertebral Complications of Multiple Myeloma: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia

  2025cites this paper
• Bone modifying agents and multikinase inhibitors as treatments for chordoma: A TriNetX-based retrospective cohort study.

  2025cites this paper
• Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task Force

  2025cites this paper
• Rescuing Mitochondrial Dysfunction in Macrophages Prevents Osteonecrosis of the Jaw in Anti‐Resorptive Therapy

  2025cites this paper
• ERRγ Promotes Multiple Myeloma Survival by Coordinating NF-κB Signaling and Mitochondrial Apoptosis Regulation

  2025cites this paper
• Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network.

  2025cites this paper
• Advances in Supportive Care for Multiple Myeloma-Related Bone Disease—A Review

  2025influential citation
• Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

  2025cites this paper
• Refractory Denosumab-induced Hypocalcemia in a High-risk Patient With Osteoblastic Metastatic Prostate Adenocarcinoma

  2025cites this paper
• HEMATOLOGICAL NEOPLASMS AND SPINE INVOLVEMENT FROM DIAGNOSIS TO TREATMENT: A LITERATURE REVIEW

  2025cites this paper
• State-of-the-art of multidisciplinary approach of bone metastasis-directed therapy: review and challenging questions for preparation of a GEMO practice guidelines

  2025cites this paper
• Risk Factors and Impact on Survival of Pathological Fractures in Patients With Humeral Metastasis

  2024cites this paper
• Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study.

  2024cites this paper
• Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer

  2024cites this paper
• Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw

  2024cites this paper
• The upconversion luminescence biomonitoring and biological properties of rare earth oxide-inorganic composite microspheres enhanced by lithium

  2024cites this paper
• Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism

  2024cites this paper
• A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma

  2024cites this paper
• Recent Advances in Minimally Invasive Local Cancer Control and Skeletal Stabilization of Periacetabular Osteolytic Metastases Under C-Arm Imaging Guidance.

  2024cites this paper
• The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab.

  2024cites this paper
• Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study

  2024cites this paper
• An assessment of the oral health status and dental care treatment needs of oncology patients receiving bone modifying agents.

  2024cites this paper
• Bilateral atypical femur fracture in a patient with breast cancer taking zoledronic acid and denosumab: a case report.

  2024cites this paper
• Supportive care in myeloma-when treating the clone alone is not enough.

  2024cites this paper
• Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments

  2024cites this paper
• First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis

  2024cites this paper
• Recent Advances in Minimally Invasive Management of Osteolytic Periacetabular Skeletal Metastases

  2024cites this paper
• Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study

  2024cites this paper
• Management of Bone Disease with Concurrent Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma.

  2024cites this paper
• Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment

  2024cites this paper
• Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials

  2024influential citation
• LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway

  2024cites this paper
• 地舒单抗与唑来膦酸治疗新诊断多发性骨髓瘤骨病的疗效及安全性

  2024cites this paper
• Remineralization Rate of Lytic Lesions of the Spine in Multiple Myeloma Patients Undergoing Radiation Therapy

  2024cites this paper
• Investigating the Underlying Molecular Mechanisms of Yunke on Bone Metastases from Prostate Cancer

  2024cites this paper
• Incidence and prevention of skeletal‐related events in multiple myeloma patients: A population‐based real‐world experience

  2024cites this paper
• [On the threshold of a possible cure: innovations in treating multiple myeloma].

  2024cites this paper
• Mitigating time toxicity in lymphoma and multiple myeloma

  2024cites this paper
• Mechanistic insights into anti‐inflammatory and immunosuppressive effects of plant secondary metabolites and their therapeutic potential for rheumatoid arthritis

  2024cites this paper
• Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma

  2024influential citation
• The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients.

  2024cites this paper
• Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma

  2024cites this paper
• Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study

  2024cites this paper
• Analysis of SIRT1 Gene SNPs and Clinical Characteristics in Medication-Related Osteonecrosis of the Jaw

  2024influential citation
• Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma

  2024cites this paper
• A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma

  2024cites this paper
• A review of mathematical modeling of bone remodeling from a systems biology perspective

  2024cites this paper
• Response of Recurrent Aggressive Aneurysmal Bone Cyst of Distal Tibia to Denosumab Treatment

  2024cites this paper
• Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors

  2024cites this paper
• Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement

  2023influential citation
• Lesions of the spinal cord caused by multiple myeloma: A systematic review and meta-analysis regarding the neurosurgical aspects of patient management

  2023cites this paper
• Risk factors associated with prognosis of patients with medication‐related osteonecrosis of the jaw

  2023cites this paper
• Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

  2023cites this paper
• Challenging Diagnosis of Lytic Bone Lesions Between Multiple Myeloma and Bone Metastasis of Primary Breast Cancer

  2023cites this paper
• Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

  2023cites this paper
• Gut microbiota deficiency ameliorates multiple myeloma and myeloma-related bone disease by Th17 cells in mice models

  2023cites this paper
• Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence

  2023cites this paper
• Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review

  2023cites this paper